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Abstract
G protein-coupled adenosine receptors are promising therapeutic targets for a wide range of 
neuropathological conditions, including Parkinson’s disease (PD). However, the ubiquity of 
adenosine receptors and the ultimate lack of selectivity of certain adenosine-based drugs have 
frequently diminished their therapeutic use. Photopharmacology is a novel approach that allows 
the spatiotemporal control of receptor function, thus circumventing some of these limitations. 
Here, we aimed to develop a light-sensitive caged adenosine A2A receptor (A2AR) antagonist to 
photocontrol movement disorders. We synthesized MRS7145 by blocking with coumarin the 5-
amino position of the selective A2AR antagonist SCH442416, which could be photoreleased upon 
violet light illumination (405 nm). First, the light-dependent pharmacological profile of MRS7145 
was determined in A2AR-expressing cells. Upon photoactivation, MRS7145 precluded A2AR 
ligand binding and agonist-induced cAMP accumulation. Next, the ability of MRS7145 to block 
A2AR in a light-dependent manner was assessed in vivo. To this end, A2AR antagonist-mediated 
locomotor activity potentiation was evaluated in brain (striatum) fiber-optic implanted mice. Upon 
irradiation (405 nm) of the dorsal striatum, MRS7145 induced significant hyperlocomotion and 
counteracted haloperidol-induced catalepsy and pilocarpine-induced tremor. Finally, its efficacy in 
reversing motor impairment was evaluated in a PD animal model, namely the hemiparkinsonian 6-
hydroxydopamine (6-OHDA)-lesioned mouse. Photo-activated MRS7145 was able to potentiate 
the number of contralateral rotations induced by L-3,4-dihydroxyphenylalanine (L-DOPA). 
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Overall, MRS7145 is a new light-operated A2AR antagonist with potential utility to manage 
movement disorders, including PD.
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1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer disease [1]. Its pathological hallmark involves the presence of intracytoplasmic 
proteinaceous neuronal inclusions in neuronal perikarya and neuronal cell processes known 
as Lewy bodies (LB). LB formation results in the degeneration of dopamine neurons in 
substantia nigra pars compacta (SNc), which causes a consequent degeneration of the 
nigrostriatal dopaminergic pathway leading to a reduction of striatal dopamine levels [2]. 
The striatum, the main input nuclei of the basal ganglia, receives information from different 
brain structures, including cortex and thalamus [3]. Neurotransmitters released at the basal 
ganglia regulate a number of brain functions, such as elicitation and learning of reward- and 
aversive stimuli-associated behaviors, motor activity control and sensorimotor gating [4,5]. 
Thus, striatal dopamine, through dopaminergic receptors, plays a central role in motor 
activity control. Indeed, degeneration of nigrostriatal dopaminergic neurons correlates well 
with the severe motor impairments shown in PD [1]. Accordingly, common PD 
pharmacotherapy aims to restore striatal dopaminergic signaling by using the dopamine 
precursor L-3,4-dihydroxyphenylalanine (L-DOPA). Alternatively, selective dopamine D2 
receptor (D2R) agonists are used [6]. However, dyskinesia and other adverse effects may 
accompany chronic D2R-based therapy [7]. Over the last two decades, alternative non-
dopaminergic drugs have been explored to ameliorate these adverse effects, including L-
DOPA-induced dyskinesia (LID) [7,8]. Among these novel substances, adenosine A2A 
receptor (A2AR) antagonists emerged as promising antiparkinsonian and antidyskinetic 
drugs [9,10], and one of them, istradefylline, was recently introduced into clinics in Japan 
(i.e. Nouriast® tablets, 20 mg) [11]. However, since A2ARs are expressed throughout the 
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body, A2AR-based medications may display off-target effects. Thus, A2AR ligands may alter 
cardiovascular function [12], platelet aggregation [13], thymocyte proliferation [14] or may 
change hippocampal neuronal activity [15], mood [16] and wakefulness [17]. Overall, the 
use of A2AR antagonists as antiparkinsonian drugs may trigger undesirable side effects, 
limiting their clinical use.
The use of optical tools in neuroscience is attracting considerable attention due to the ability 
to dissect neural circuits with high spatiotemporal resolution [18,19]. Photopharmacology, as 
distinct from optogenetics, which requires the genetic introduction of light-sensitive proteins 
(i.e. channels or receptors), uses light-sensitive molecules that modulate endogenous targets 
upon local irradiation [20,21]. As a consequence, photoactive drugs offer superior tissue 
specificity and reduced off-target effects [20]. Two types of photosensitive drugs are used in 
photopharmacology, namely photoswitchable molecules and caged-compounds [20,21]. 
Previously, we developed a photoisomerizable nonselective adenosine receptor agonist, 
MRS5543, which behaved as a partial A2AR agonist in the dark (trans isomer), while upon 
blue (i.e. 460 nm) light irradiation it became an antagonist [22]. However, the lack of 
selectivity and short lifetime (i.e. milliseconds) of the photo-induced cis configuration 
rendered the compound not suitable for in vivo A2AR blockade. Therefore, we aimed to 
overcome these pharmacological or photochemical drawbacks associated with 
photoswitchable compounds and thus we developed a caged-A2AR antagonist, namely 
MRS7145, to achieve amenable temporal receptor photocontrol in behaving animals. 
Interestingly, MRS7145 showed light-dependent A2AR antagonist activity in living cells. In 
addition, in vivo MRS7145 photorelease allowed motor activity control and showed light-
dependent antiparkinsonian-like efficacy in mice.
2. Materials and methods
2.1. Synthesis of MRS7145
MRS7145 synthesis is described in detail in the Supplementary Information and 
supplementary Fig. 1 [23]. All NMR spectral assignments were determined with 1H (400 
MHz), 13C (100 MHz) in CDCl3 (Supplementary Fig. 2). Peaks were referenced to residual 
chloroform signals (δH 7.26 ppm, or δC 77.0 ppm). High resolution mass spectra were 
recorded on an ESI-TOF instrument.
2.2. Photochemical characterization
To monitor MRS7145 photo-uncaging, a 20 μM solution of this compound in PBS:DMSO 
1:1 at 37°C was irradiated at 405 nm and 3 mW with a cw diode laser, and spectral changes 
were monitored by UV-vis absorption spectroscopy in an UV-vis HP 8453 
spectrophotometer (Agilent Technologies, Inc., Colorado Springs, CO, USA). Control 
experiments were conducted by irradiating SCH442416 (Tocris Bioscience) and 7-
diethylamino-4-hydroxymethylcoumarin (Indofine Chemical Co., Hillsborough, NJ) 
solutions at the same conditions. Photo-uncaging quantum yields were determined using the 
photoisomerization process of trans-azobenzene in acetonitrile as a reference and following 
the methodology described [24].
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2.3. Cell culture and stable transfection
Human embryonic kidney (HEK)-293T cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 1 mM sodium 
pyruvate, 2 mM L-glutamine, 100 U/mL streptomycin, 100 mg/mL penicillin and 5% (v/v) 
fetal bovine serum at 37°C and in an atmosphere of 5% CO2. HEK-293 cells growing in 60 
cm2 plates were transfected with the cDNA encoding the CFP-tagged human A2AR 
(A2ARCFP) [25] using TransFectin™ Lipid Reagent (Bio-Rad Laboratories, Hercules, CA, 
USA). Fluorescent cells were selected every 2 weeks for 2 months using a Cell sorter 
(MoFlo Astrios, Beckman Coulter) to enrich the percentage of cells that express the 
receptor, thus ensuring its permanent expression.
2.4. Synthesis of MRS5842
The fluorescent dye Alexa-647 was covalently attached to the A2AR agonist 2-[[2-[4-[2-(2-
aminoethyl)-aminocarbonyl]ethyl]phenyl]ethylamino]-5′-N-ethyl-carboxamidoadenosine 
(APEC) to generate the MRS5842 or APEC647, which was purified by HPLC. The synthesis 
is described in detail in the Supporting Information (Supplementary Fig. 1 and 2)
2.5. Flow cytometry competition binding assays
Receptor binding studies were performed in HEK-293T cells permanently expressing 
A2ARCFP using the APEC647 as previously described [26]. In brief, cells were detached with 
accutase (Sigma-Aldrich) and resuspended in Hank’s balanced salt solution (HBSS) 
containing 1 mg/ml glucose and 0.1% BSA. Cells (8 × 105 cells/200μl) were firstly 
incubated with vehicle, MRS7145 (1 μM) or SCH442416 (1 μM, Tocris Bioscience) in 
silicone-coated reaction vessels and irradiated at 405 nm with a LED (Doric Connectorized 
LED, Doric Lenses Inc., Quebec, Canada) using an optic fiber 
(MFP_400/440/900-0.53_0.5m_FC-SMC, Doric Lenses Inc) or mock manipulated (dark) for 
5 min. The 405 nm light pulses lasted 500 ms each and were administered at 23 mW output 
power and 1 Hz frequency. After 5 min, post-irradiated cells were incubated with APEC647 
(100 nM) during 60 min at 22°C and used directly for flow cytometric measurements. For 
each binding condition tested, 2 × 104 cells were analyzed using a FACSCanto™ flow 
cytometer (Becton Dickinson, Heidelberg, Germany) with excitation at 633 nm (red laser) 
and emission at 660/20 nm. Samples were maintained in the dark during the analysis to 
avoid photobleaching. Fluorescence events were obtained in the FL-1 channel 
(Supplementary Fig. 5). Data were collected using Cell Quest Pro software (BD, Franklin 
Lakes, NJ) and analyzed by GraphPad Prism 6.01 (GraphPad Software, La Jolla, CA, USA).
2.6. cAMP accumulation inhibition assay
cAMP accumulation was measured using the LANCE Ultra cAMP kit (PerkinElmer, 
Waltham, MA, USA) as previously described [27]. In brief, A2AR HEK-293T cells were 
detached with accutase (Sigma-Aldrich) and incubated for 1 h at 22°C in Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma-Aldrich) supplemented with 0.1% BSA, 
adenosine deaminase (ADA, 0.5 U/ml; Roche Diagnostics, GmbH, Mannheim, Germany) 
and Zardaverin (100 μM; Calbiochem, San Diego, CA, USA). Cells (1×104 cells/200μl) 
were firstly incubated with vehicle or MRS7145 (10 μM or increasing concentrations) and 
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then irradiated as above indicated. After 5 min, post-irradiated cells were incubated with 
CGS21680 (10 nM or increasing concentrations) during 30 min at 22°C. Eu-cAMP tracer 
and ULight™-anti-cAMP reagents were prepared and added to the sample following 
manufacturer’s instructions. The 384-wells plate was incubated 1 h at 22°C in the dark and 
was then read on a POLARstar microplate reader (BMG Labtech, Durham, NC, USA). 
Measurements at 620 nm and 665 nm were used to detect the TR-FRET signal and the 
concomitant cAMP levels were calculated following manufacturer’s instructions. Data were 
fitted by non-linear regression using GraphPad Prism 6.01.
2.7. Immunohistochemistry
Mice were anesthetized and intracardially perfused with 100 ml of ice-cold 4% 
paraformaldehyde (PFA) in phosphate buffered saline (PBS; 8.07 mM Na2HPO4, 1.47 mM 
KH2PO4, 137 mM NaCl, 0.27 mM KCl, pH 7.2). Brains were post-fixed overnight in the 
same solution of PFA at 4°C. Coronal sections (50 μm) were obtained using a vibratome 
(Leica Lasertechnik GmbH, Heidelberg, Germany). Slices were collected in Walter’s 
antifreezing solution (30% glycerol, 30% ethylene glycol in PBS, pH 7.2) and kept at −20°C 
until processing. For immunohistochemistry of brain slices, these were washed three times 
with PBS, permeabilized with 0.5% Triton X-100 in PBS for 2 h and rinsed again three 
times with washing solution (0.05% Triton X-100 in PBS). The slices were then incubated 
with washing solution containing 10% normal donkey serum (NDS; Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 2 h at room temperature. 
Subsequently, slices were incubated with rabbit anti-TH (3 μg/ml; Millipore, Billerica, MA, 
USA) or goat anti-A2AR (3 μg/ml; Santa Cruz Biotechnology, Dallas, TX, USA) in washing 
solution containing 10% NDS for 48h at 4°C. Next, slices were washed with washing 
solution containing 1% NDS before the incubation with Cy2-conjugated donkey anti-rabbit 
or anti-goat IgG antibody (1:200; Jackson ImmunoResearch Laboratories, West Grove, PA, 
USA) in washing solution for 2 h at room temperature. Finally, slices were washed twice 
with washing solution containing 1% NDS and then mounted with Vectashield 
immunofluorescence medium (Vector Laboratories, Peterborough, UK) in glass slides. 
Fluorescence striatal images were captured using a Leica TCS 4D confocal scanning laser 
microscope (Leica Lasertechnik GmbH).
2.8. Animals
CD-1 mice (animal facility of University of Barcelona) at 5 weeks of age were used. The 
University of Barcelona Committee on Animal Use and Care approved the protocols. 
Animals were housed and tested in compliance with the guidelines described in the Guide 
for the Care and Use of Laboratory Animals [28] and following the European Union 
directives (2010/63/EU). All efforts were made to minimize animal suffering and the 
number of animals used. Animals were housed in groups of five in standard cages with ad-
libitum access to food and water and maintained under controlled standard conditions (12 h 
dark/light cycle starting at 7:30 AM, 22°C temperature and 66% humidity).
2.9. Brain optic fiber implantation
Mice were anesthetized by administering (intraperitoneally, i.p.) a mixture of ketamine (100 
mg/kg, Merial, Spain)/xylazine (10 mg/kg, Calier, Spain). Optical fibers 
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(TFC_400/475-0.53_3.0mm_TSM4.0_B45 or MFC_400/475-0.53_2.5mm_TSM4.0_B45, 
Doric Lenses Inc) were stereotaxically (Kopf Instruments, Tujunga, USA) implanted at 
coordinates: i) AP=+0.5, ML=±2.0, DV=−3.0 for the TFC (Two Ferrule Cannule) and; ii) 
AP=+0.5, ML=+2.0, DV=−2.5 for MFC (Mono Ferrule Cannule), following to the atlas of 
Paxinos and Franklin [29] (Supplementary Fig. 7B and C). Chirurgic steel anchor screws 2 
mm long with a thread of 1 mm O.D. (Agnthos, Lidingö, Sweden) were used. Screws were 
placed at AP=−3.0, ML=±2.0 and predrilled holes were made with a 0.7 mm drill bit. 
Finally, a plastic ring was placed to the skull to encompass optical fibers and screws. The 
ring was filled with dental cement (DENTALON plus, Heraeus Kulzer GmbH, Germany) to 
embrace all the elements together. After optic fiber implantation mice were treated with 
Meloxicam (1 mg/kg, Boehringer Ingelheim, Germany) for three days and they were 
checked routinely for one week.
2.10. Locomotor activity tests
The open field test was used to evaluate the spontaneous or drug-induced locomotor activity 
in TFC-implanted CD-1 mice. In brief, animals were administered (i.p.) with MRS7145 (3 
mg/kg), SCH442416 (3 mg/kg, Tocris Bioscience) or vehicle-saline with 5% DMSO and 5% 
Tween-20 min before the testing session. Non-habituated mice were placed in the center of 
an activity field arena (30 × 30 cm, surrounded by four 50 cm-high black painted walls) 
equipped with a camera above to record activity and connected to the light source. Animals 
were either irradiated with a LED-based fiber optic system (Doric Lenses Inc) at 405nm 
light or mock manipulated (dark) for 20 min during the testing session. The 405 nm light 
pulses lasted 500 ms each and were administered at 23 mW output power and 1 Hz 
frequency. The exploratory behavior of the animals was monitored during a 30-min period. 
The total distance travelled was analyzed using Spot tracker function from Image J (NIH).
2.11. Catalepsy test
Catalepsy was induced in TFC-implanted CD-1 mice by the administration (i.p.) of 
haloperidol (1 mg/kg; Tocris Biosciences, Bristol, UK). After one h, haloperidol-induced 
catalepsy was measured as the duration in seconds of an abnormal upright posture in which 
the forepaws of the mouse were placed on a horizontal wooden bar (0.6 cm of diameter) that 
was located 4.5 cm above the floor. Subsequently, mice were administered (i.p.) with either 
vehicle (i.e. saline with 5% DMSO and 5% Tween), SCH442416 (3 mg/kg, Tocris 
Bioscience) or MRS7145 (3 mg/kg). After 20 min, animals were irradiated at 405 nm 
following the above indicated light protocol, and a second haloperidol-induced catalepsy 
measurement was performed.
2.12. Tremulous Jaw Movements
Mice were administered (i.p.) with either vehicle (i.e. saline containing 5% DMSO and 5% 
Tween), SCH442416 (3 mg/kg, Tocris Bioscience) or MRS7145 (3 mg/kg). After 20 min, 
animals were irradiated at 405 nm following the above indicated light protocol. 
Subsequently, tremulous jaw movements (TJMs) were induced by the administration (i.p.) of 
pilocarpine (1 mg/kg; Sigma-Aldrich). Mice were placed in the observation chamber (i.e. 
14.4 × 7.6 × 7 cm clear glass chamber elevated 40 cm from the floor) and allowed 10 min to 
habituate before TJMs were recorded for 10 min. TJMs were defined as rapid vertical 
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deflections of the lower jaw that resembled chewing but were not directed at any particular 
stimulus [30].
2.13. 6-Hydroxydopamine lesion
6-Hydroxydopamine (6-OHDA) lesion was performed as previously described [25]. Briefly, 
two-month old mice were anesthetized (see above) and one microliter of freshly prepared 6-
OHDA solution (3.2 mg/ml free base in 0.02% ascorbate-saline) was stereotaxically (Kopf 
Instruments) injected at the medial forebrain bundle (MFB) using the following coordinates: 
AP=−1.2, ML=−1.3, DV=−4.7 (Supplementary Fig. 7A and C). The injections were 
performed at a rate of 0.5 μl/min using a 10-μl Hamilton syringe. The Hamilton syringe was 
left in place for 2 min before and 2 min after the injection. After surgery, mice were treated 
with Meloxicam (1 mg/kg, Boehringer Ingelheim, Germany) for three days and they were 
checked routinely for one week. Three weeks after the lesion, the extent of dopamine 
deafferentation was validated by assessing the rotating behavioral response to apomorphine 
administration. In brief, mice were injected with apomorphine (3 mg/kg, i.p.; Sigma-
Aldrich) and the number of full contralateral turns recorded during a 1 h period. Dopamine 
depletion was considered successful in those animals that made at least 200 net contralateral 
rotations. Thereafter, an optic fiber (MFC) was implanted in animals with higher scores in a 
second operation as described above. Finally, animals were housed during three weeks 
before use.
2.14. Rotational test
6-OHDA lesioned animals were treated (i.p.) with benserazide hydrochloride (25 mg/kg; 
Sigma-Aldrich), L-DOPA methyl ester (submaximal dose: 4 mg/kg; Sigma-Aldrich) and 
either vehicle, MRS7145 (3 mg/kg) or SCH442416 (3 mg/kg, Tocris Bioscience). After 10 
min, animals were placed in a white cylinder (30 × 10 cm diameter) equipped with a camera 
above and connected to the light source. Animals were irradiated with a LED-based fiber 
optic system (Doric Lenses Inc.) at 405 nm or mock manipulated (dark) for 20 min during 
the testing session. The 405 nm light pulses lasted 500 ms each and were administered at 23 
mW output power and 1 Hz frequency. The rotational behavior of animals was monitored 
during a 40-min period. Each 360° clock-wise or counter clock-wise turn was manually 
counted from the movie generated.
2.15. Statistical analysis
The number of samples or animals (n) for each set of experiments is indicated in the figure 
legends. Statistical analysis was performed by one-way ANOVA with Tukey multiple 
comparison test or Student’s t-test when appropriate. Statistical significance was considered 
at P < 0.05.
3. Results
3.1. Design and synthesis of a caged A2AR antagonist
The A2AR-based ligand MRS7145 was synthesized (Supplementary Fig. 1 and 2) by 
modifying the amino group of SCH442416, a selective A2AR antagonist [31], to generate a 
carbamate derivative containing violet light-absorbing coumarin (Fig. 1A). Subsequently, we 
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characterized MRS7145 photochemically. The UV-vis absorption spectrum of MRS7145 
showed signals arising from its two different building blocks: a peak at ca. 265 nm, which fit 
well the absorption maximum found for SCH442416, and another band at ca. 385 nm 
corresponding to the coumarin unit (7-diethylamino-4-hydroxymethylcoumarin, Fig. 1B). 
The photochemical behavior of MRS7145 was then explored upon selective coumarin 
excitation at 405 nm. This wavelength was chosen based on previous results showing its 
safety and efficacy for in vivo uncaging [32]. Indeed, whereas no photodegradation of 
SCH442416 and the separated coumarin chromophore was observed under these irradiation 
conditions (Supplementary Fig. 4), spectral changes were registered for MRS7145 that are 
consistent with the photolysis of the coumarin benzylic bond and the release of the appended 
SCH442416 fragment [32] (Fig. 1C). A photo-uncaging quantum yield of Φchem = 0.01 was 
determined for this process, which is in fair agreement with the photochemical behavior 
reported for other biologically-active pyrimidine derivatives caged with 7-diethylamino-4-
hydroxymethylcoumarin [33,34].
3.2. Optical control of A2AR function in cultured cells
We assessed the light-dependent MRS7145-mediated A2AR blockade by using a new 
fluorescent ligand binding assay and classical cAMP accumulation experiments in cells 
expressing A2AR. First, a new A2AR fluorescent agonist (i.e. APEC647) (Supplementary Fig. 
3) was synthesized and used in a flow cytometry-based ligand binding assay [26]. The 
characterization of APEC647 binding to A2AR expressed in HEK-293T cells (Fig. 2A) 
revealed a dissociation constant within the nanomolar range (Kd = 20 ± 5 nM) 
(Supplementary Fig. 5). We then performed displacement experiments of APEC647 with 
SCH442416 and MRS7145 in the absence and presence of light. As expected, SCH442416 
fully displaced bound APEC647 regardless of the illumination conditions (Fig. 2B), while 
MRS7145 displaced bound APEC647 only upon 405 nm cell irradiation (Fig. 2B), thus 
demonstrating its light-dependent activity. Next, we assessed the light-dependent MRS7145-
mediated modulation of cAMP accumulation induced by A2AR activation. To this end, 
increasing concentrations of a prototypical A2AR full agonist (i.e. CGS21680) were 
incubated in the absence or presence of MRS7145 and under different irradiation conditions 
(Fig. 2C). In the dark, CGS21680 induced a dose-dependent increase of cAMP accumulation 
with low nanomolar potency both in saline- and MRS7145-treated cells (pEC50 = 9.2 ± 0.1 
and pEC50 = 8.6 ± 0.1, respectively) and with comparable efficacy (Fig. 2C). Conversely, 
while light neither affected potency nor efficacy of saline-treated cells (data not shown), 405 
nm irradiation of MRS7145-incubated cells abolished CGS21680-induced cAMP 
accumulation (Fig. 2C). In addition, MRS7145 was able to preclude A2AR-mediated cAMP 
accumulation in a light- and dose-dependent manner (pEC50 = 8.3 ± 0.1) (Fig. 2D). Overall, 
these results revealed a low nanomolar potency for the light-dependent MRS7145-mediated 
A2AR blockade in cultured cells.
3.3. Light-dependent efficacy of MRS7145 in animal models of movement disorders
Once MRS7145 light-dependent activity was validated in living cells, we aimed to assess its 
efficacy in animal behavior. We first evaluated the impact of striatal MRS7145 uncaging in 
the spontaneous locomotor activity of mice. To this end, a dual fiber-optic cannula was 
implanted in the dorsal striatum (Fig. 3A), and spontaneous locomotion assessed after 
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administration (i.p.) of vehicle, SCH442416 or MRS7145, in the absence and presence of 
light (405 nm) (Fig. 3B). SCH442416 produced a significant increase in the spontaneous 
locomotor activity of freely moving animals, regardless the illumination paradigm (Fig. 3B 
and C). Importantly, while MRS7145 did not alter spontaneous locomotion in non-irradiated 
mice, it significantly (P < 0.001) increased locomotor activity upon 405 nm light striatal 
irradiation (Fig. 3B and C). Coumarin alone did not have any effect on spontaneous 
locomotion at any dose tested (0.5-6.0 mg/kg) (Supplementary Fig. 6). Overall, these results 
demonstrated the ability to uncage (at 405 nm) MRS7145 in the dorsal striatum of mice, and 
to manipulate the spontaneous locomotor activity of freely moving animals.
Next, we assessed the in vivo light-dependent efficacy of MRS7145 in two animal models 
that mimic two PD symptoms, namely rigidity and tremor. We first evaluated the light-
dependent effects of MRS7145 on haloperidol-induced catalepsy. While SCH442416 
showed a light independent anticataleptic activity (Fig. 3D), as expected [35], MRS7145 was 
only able to reverse haloperidol-induced catalepsy upon 405 nm light striatal irradiation 
(Fig. 3D). Next, we evaluated the efficacy of MRS7145 to counteract pilocarpine-induced 
tremulous jaw movement (TJM). Again, SCH442416 showed a light-independent 
antitremulous activity (Fig. 3E), as previously reported [36]. And similarly, MRS7145 was 
unable to reverse TJM in dark conditions, while it fully blocked (P < 0.001) pilocarpine-
induced TJM upon 405 nm light striatal irradiation (Fig. 3E). Overall, these results 
demonstrated the efficacy of striatal MRS7145 photo-uncaging in animal models of 
movement disorders.
3.4. Light-dependent antiparkinsonian-like efficacy of MRS7145
To reinforce the notion that MRS7145 photo-uncaging in the dorsal striatum would be a 
valuable approach for PD treatment, we evaluated the effects of MRS7145 in the unilateral 
6-hydroxydopamine (6-OHDA)-lesioned mouse PD model. To this end, we lesioned the 
medial forebrain bundle (MFB) of the right hemisphere (Supplementary Fig. 7A and C), as 
previously described [25]. Mice showing significant dopamine denervation (see Materials 
and Methods) underwent surgery to implant a single optical fiber at the 6-OHDA lesioned 
hemisphere (Fig. 4A). As expected for A2AR antagonists [37], SCH442416 potentiated the 
contralateral rotations induced by a submaximal L-DOPA dose (4 mg/kg) (Fig. 4B). This 
antiparkinsonian-like activity of SCH442416 was unaffected by 405 nm light hemi-
irradiation. On the other hand, MRS7145 was unable to potentiate L-DOPA-induced 
contralateral rotations in dark conditions; while, upon irradiation, it significantly (P < 0.05) 
enhanced the rotational behavior of the hemiparkinsonian mice (Fig. 4B and Video 1). 
Overall, these results demonstrated a MRS7145 light-dependent antiparkinsonian-like 
efficacy, thus revealing the ability to photo-control A2AR function in the dorsal striatum.
4. Discussion
The findings reported in the present study provide compelling evidence regarding: i) the 
feasibility of remotely controlling A2AR function in vivo, and ii) the putative usefulness of 
photo-active drugs in the management of movement disorders. To our knowledge, MRS7145 
is the first compound able to block A2AR in a light-dependent manner, not only in living 
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cells, but also in behaving animals. Accordingly, MRS7145 photoactivation with violet light 
precluded A2AR signaling in cultured cells, while photo-uncaging in the mice dorsal 
striatum prompted hyperlocomotion, counteracted haloperidol-induced catalepsy and 
pilocarpine-induced tremor, and reversed motor impairments in a PD model.
It has been clinically demonstrated that A2AR antagonists are effective in improving PD 
motor dysfunction, both in monotherapy [38] and in combination with L-DOPA or other 
antiparkinsonian drugs [39]. However, further clinical development has been compromised, 
in part due to the ubiquity of A2AR, which may produce some mild to severe adverse 
antagonist effects, including insomnia, headache, constipation, hallucinations, asthma, 
infection, urosepsis or cardiac failure [37,40]. Indeed, classical pharmacology displays some 
important drawbacks: i) slow and imprecise drug delivery; ii) low specificity (i.e. drugs 
producing more than one effect); and iii) effects are non-resolved, either in space or time 
(i.e. drugs are usually active in every tissue they reach, until they are degraded or 
eliminated). The optical control of A2AR with photosensitive antagonists (i.e. MRS7145) 
may provide enough spatiotemporal resolution to circumvent these drawbacks, limiting off-
target effects, and also allowing to locally adjust dosage. In addition, the use of light may 
permit mapping A2AR function, not only in the striatum but also in other brain regions (i.e. 
cortex, hippocampus, thalamus), thus contributing to dissect the adenosinergic system 
circuitry within the brain. Indeed, it may help to understand the presence of extrastriatal 
A2AR, which could have opposing functions to striatal A2AR, as recently demonstrated [41]. 
Overall, our data support that MRS7145-based spatiotemporal A2AR manipulation may 
contribute not only to the mechanistic understanding of the brain adenosinergic system, but 
it also may permit exploring photo-dependent approaches, leading to a better management of 
movement disorders.
Using light for pharmacological applications (i.e. photopharmacology) might represent a 
way to circumvent some classical pharmacological shortcomings. However, the irradiation 
of a tissue non-naturally exposed to light might possibly induce some damage. The majority 
of photoactivable compounds already used in biology require potentially harmful UV 
radiation [42], which also displays a poor tissue penetration depth. Consequently, current 
photocaged compounds are unacceptable for in vivo and clinical use and are limited to in 
vitro applications. Here, we designed and synthesized a selective photocaged A2AR 
antagonist with effective in vitro and in vivo uncaging at 405 nm (visible spectrum), which 
upon exposure to a specific irradiation protocol was shown to be non-toxic for neurons [32]. 
On the other hand, the use of photocaged compounds to modify neuronal activity may 
provide some advantages over other related approaches, namely optogenetics and deep brain 
stimulation (DBS). Unlike optogenetics, photopharmacology does not require viral-mediated 
gene delivery of photosensitive proteins, thus avoiding certain ethical considerations. In 
addition, optogenetics does not allow the direct blockade of a specific endogenous receptor, 
whereas photopharmacology permits both agonism and antagonism activity assessment. 
DBS has a great temporal resolution, but it displays two major drawbacks, namely a lack of 
cell-type specificity and electrode-glia encapsulation. First, glial cells increase impedance 
and demand high—electrical currents to reach the desired areas, which leads to a lower 
spatial resolution of DBS than that exhibited by caged compounds. In addition, glia 
encapsulation is a major problem associated with DBS. It may also affect optical fibers but 
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to a lesser extent, since glial cells are optically transparent [43]. Finally, it is important to 
note that one important drawback of photocaged compounds (i.e. MRS7145) would be their 
irreversible nature. In this sense, the design and development of novel photoswitchable 
compounds with high selectivity and longer lifetimes may permit a better temporal 
resolution. In addition, the development of novel wireless optical fibers, which have been 
already designed and tested [44], may enable a substantial growth of photopharmacology in 
the near future.
5. Conclusions
Action of conventional drugs is often limited by a lack of temporal and site specificity, 
leading to side effects that can impede their clinical development. Photopharmacology 
combines the power of light and pharmacology for spatiotemporal resolution of drug action 
in vivo, thus limiting off-target effects and allowing local dose adjustments. Here, we 
developed the first adenosine A2A receptor antagonist endowed with light-dependent 
activity.
In conclusion, MRS7145 is the first photo-controlled A2AR antagonist capable of binding 
and blocking A2AR in a light-dependent fashion in living cells. Upon local brain irradiation, 
MRS7145 allows the fine control of spontaneous locomotor activity and reversal of 
pharmacologically-induced Parkinsonian-like behavior. Our data demonstrate that this 
compound can be effectively photo-delivered in the striatum of rodents, increasing 
locomotor activity while reverting pharmacologically-induced parkinsonian-like symptoms. 
Our results constitute a proof of concept to design novel approaches for movement disorder 
management.
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Figure 1. Design, synthesis and photochemical properties of MRS7145
(A) The synthesis of MRS7145 involves a procedure using SCH442416 and 7-
diethylamino-4-hydroxymethylcoumarin (coumarin). In brief, 60% NaH was first added to a 
solution of SCH442416 and 18-crown-6. After 15 min, a solution of the coumarin 
nitrophenyl carbonate was added. After 1 h, DMF was co-evaporated onto SiO2 with toluene 
(3 ×) and chromatographed with 20 to 100% EtOAc/hexanes (see Materials and Methods). 
Upon irradiation with 405 nm visible light the irreversible photolytic reaction produced 
SCH442416. (B) Absorption spectra of 7-diethylamino-4-hydroxymethylcoumarin, 
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SCH442416 and MRS7145 in PBS:DMSO 1:1 and 37 °C. (C) Time-course of spectral 
changes registered for MRS7145 in PBS:DMSO 1:1 upon irradiation at 405 nm and 37 °C 
during 30 min, which are consistent with the light-induced uncaging of SCH442416.
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Figure 2. MRS7145-dependent photo-control of exogenously and endogenously expressed 
adenosine A2A receptor in cultured cells
(A) HEK-293 cells stably transfected with the human CFP-tagged adenosine A2A receptor 
(A2ARCFP) were perfused with APEC647 (MRS5842) (1 μM) in the absence and presence of 
SCH442416 (1 μM). (B) The binding properties of MRS7145 were measured by a flow 
cytometer throughout the incubation of APEC647 (100 nM) in A2AR-CFP cells in the 
presence of SCH442416 (1 μM) or MRS7145 (1 μM), all in dark conditions and upon 
irradiation at 405 nm. Data was expressed as a percentage of the specific events within the 
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fluorescent region of analysis (Supplementary Fig. 5). The percentage of binding was 
calculated as described in Materials and Methods and expressed as mean ± SEM (n=4). 
*P<0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, one-way ANOVA with a Tukey’s 
multiple comparison test using the Veh+dark condition as a control. #P<0.05, ## P < 0.01, 
### P < 0.001, #### P < 0.0001, Student’s t-test when comparing dark vs 405 nm 
conditions. Similar results were obtained in three independent experiments. (C) 
Determination of A2AR-mediated cAMP accumulation in A2AR-CFP cells. Normalized 
dose-response of CGS21680-induced cAMP accumulation in the absence (grey circles) or 
presence of MRS7145 in dark conditions (black squares) and upon irradiation at 405 nm 
(violet squares) are shown. (D) cAMP accumulation in A2AR-CFP cells stimulated with 
CGS21680 (10 nM) in the absence or presence of increasing concentrations of MRS7145, 
both in dark conditions (black squares) and upon irradiation at 405 nm (violet squares). The 
percentage of cAMP accumulation was calculated as described in Materials and Methods 
and expressed as mean ± SEM (n=3). Similar results were obtained in three independent 
experiments.
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Figure 3. In vivo assessment of MRS7145 light-dependent effect
(A) Photomicrographs showing A2AR immunofluorescence staining in a brain coronal 
sections. The arrows show where the double optic fiber was implanted in the dorsal striatum. 
(B) Representative 30 min trajectories in an open field arena using either Vehicle, 
SCH442416 or MRS7145 either in dark (black) or 405 nm (violet) conditions. (C) 
Quantification of total horizontal locomotor activity shown in (B) was measured as the total 
distance travelled. In the upper panel, a scheme of the 405 nm light irradiation protocol 
(violet rectangles) and open field locomotor activity recordings (blue rectangle) is shown. In 
brief, animals were administered with vehicle (Veh, i.p.), SCH442416 (SCH, 3 mg/kg, i.p.) 
or MRS7145 (MRS, 3 mg/kg, i.p.) 20 min before the striatum was irradiated at 405 nm or 
mock manipulated (dark) for 20 min. Mice were recorded for 30 min, during the irradiation 
(20 min) and 10 min after. (D) Haloperidol-induced cataleptic behaviour was measured as 
the time spent with both front paws resting on the bar (see Materials and Methods). A cut-
off time was set at 200 sec. Animals were intraperitoneally injected with haloperidol (1 mg/
kg), and after 1 h either vehicle (Veh, 5% DMSO and 5% Tween-80 in saline), SCH442416 
(SCH, 3 mg/kg) or MRS7145 (MRS, 3 mg/kg) were administrated. After 20 min, the 
striatum was irradiated at 405 nm (or dark) for 20 min. Cataleptic time was measured 
afterwards. (E) Pilocarpine-induced tremulous jaw movements (TJMs) were measured as the 
number of chewing movements done in 10 min (see Materials and Methods). Animals were 
intraperitoneally injected with either vehicle (Veh, 5% DMSO and 5% Tween-80 in saline), 
SCH442416 (SCH, 3 mg/kg) or MRS7145 (MRS, 3 mg/kg) 20 min before the striatum was 
irradiated at 405 nm (or dark) for 20 min. Pilocarpine (1 mg/kg) was then administrated and 
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the animal was placed in the observation box for 10 min. The number of purposeless 
chewing movements were recorded for the last 10 min period using a hand counter. (C-E) 
Data (means ± SEM, 5-10 mice per group) over the Veh+dark value. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001, one-way ANOVA with a Tukey’s multiple comparison test 
using the Veh+dark condition as a control. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 
0.0001, Student’s t-test when comparing dark vs 405 nm conditions.
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Figure 4. In vivo evaluation of MRS7145 in an optic-fiber implanted and unilateral 6-OHDA-
lesioned mouse model
(A) Photomicrograph showing tyrosine hydroxylase (TH) and A2AR immunofluorescence 
staining in brain coronal sections. A loss of dopaminergic innervation in the lesioned (L) 
compared to the non-lesioned (R) striatum is observed. The arrow indicates where the single 
optic fiber was implanted. (B) MRS7145-mediated potentiation of L-DOPA-induced 
contralateral rotations were monitored during a 40 min period (see Materials and Methods). 
Animals were intraperitoneally injected with benserazide (25 mg/kg), followed by a 
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submaximal dose of L-DOPA (4 mg/kg), and finally injected with either vehicle (Veh, 5% 
DMSO and 5% Tween-80 in saline), SCH442416 (SCH, 3 mg/kg) or MRS7145 (MRS, 3 
mg/kg) 10 min before the right striatum was irradiated at 405 nm (or dark) for 20 min. Data 
(means ± SEM, 5-10 mice per group) over the Veh+dark value. *P<0.05, ** P < 0.01, *** P 
< 0.001, **** P < 0.0001, one-way ANOVA with a Tukey’s multiple comparison test using 
the Veh+dark condition as a control. #P<0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001, 
Student’s t-test when comparing dark vs 405 nm conditions.
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